BDX vs DHR vs GRFS Stock Comparison

Becton Dickinson, Danaher and Grifols Prices as of Oct 26, 2026 Peers: Industry group
BDX Becton Dickinson & Co
$196.39 +6.8% 1M +5.7% 1Y
Market cap
$53.62B
P/E
57.0x
Revenue (TTM)
$23.25B
Div. yield
–
Medical Supplies Healthcare
4 wins
DHR Danaher Corp /De/
$232.95 +3.7% 1M +4.5% 1Y
Market cap
$163.71B
P/E
40.9x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
5 wins
GRFS Grifols SA
$7.92 +7.8% 1M -16.3% 1Y
Market cap
$5.43B
P/E
11.9x
Revenue (TTM)
—
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

11 decided of 12

Danaher leads on 5 of the 12 questions below (Danaher 5, Becton Dickinson 4, Grifols 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBDXDHRGRFSLeader
Larger companyMarket capitalisation $53.62B $163.71B $5.43B DHR
Cheaper on earningsLower P/E, profitable companies only 57.0x 40.9x 11.9x GRFS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 15.1x 25.6x 8.4x GRFS
Faster revenue growthRevenue growth, trailing twelve months +17.4% +4.6% — BDX
More profitableNet margin, trailing twelve months 4.0% 15.9% — DHR
Better return on capitalReturn on invested capital 5.3% 5.7% — DHR
Less leveragedLower net debt / EBITDA 3.2x 2.9x — DHR
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +5.7% +4.5% -16.3% BDX
Better 5-year returnAnnualised price return, 5 years -4.3%/yr -5.3%/yr -9.9%/yr BDX
Less volatileAnnualised volatility, 1 year 31.9% 30.7% 32.4% DHR
Higher overall scoreMean of the five percentile scores vs peers 67/100 59/100 57/100 BDX

Percentile Scorecard

BDXDHRGRFS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBDXDHRGRFS
Valuation 90 #24 of 228 67 #75 of 228 99 #6 of 626
Growth 47 #117 of 221 21 #176 of 221 –
Profitability 78 #46 of 208 88 #26 of 208 –
Financial Health 27 #176 of 239 46 #130 of 239 14 #566 of 658
Shareholder Returns 95 #8 of 137 76 #34 of 137 56 #161 of 368
Overall 67 59 57
  • BDX ranked among 248 companies in Medical Devices and Diagnostics
  • DHR ranked among 248 companies in Medical Devices and Diagnostics
  • GRFS ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBDXDHRGRFSSPY
1 month +6.8%+3.7%+7.8% -0.8%
3 months +23.6%+18.5%+2.2% +3.5%
6 months +30.7%+29.0%-2.6% +7.0%
Year to date +1.2%+1.8%-15.3% +12.2%
1 year +5.7%+4.5%-16.3% +13.0%
3 years -21.9%+24.0%+1.0% +86.3%
3 years, per year -7.9%+7.4%+0.3% +23.1%
5 years -19.8%-23.7%-40.5% +68.6%
5 years, per year -4.3%-5.3%-9.9% +11.0%
10 years +17.2%+199.7%-46.6% +258.0%
10 years, per year +1.6%+11.6%-6.1% +13.6%

Risk

MeasureBDXDHRGRFSSPY
Volatility, 1Y 31.9%30.7%32.4% 12.7%
Downside volatility, 1Y 33.1%31.8%34.1% 12.7%
Beta vs S&P 500, 1Y 0.340.450.95 1.00
Return / volatility, 1Y 0.180.15-0.50 1.02
Max drawdown, 5Y -50.4%-50.8%-58.9% -25.4%
From 52-week high -6.5%-3.8%-18.5% -1.8%
52-week high $210.02$242.05$9.72 $779.14
52-week low $140.71$161.91$7.02 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBDXDHRGRFS
P/E now vs peer median 57.3xmedian 30.6x 41.0xmedian 30.6x 11.9xmedian 17.1x
P/S now vs peer median 2.3xmedian 3.0x 6.5xmedian 3.0x 0.6xmedian 8.8x
EV/EBITDA now vs peer median 14.0xmedian 17.5x 24.3xmedian 17.5x —median 17.1x
P/FCF now vs peer median 16.7xmedian 23.3x 30.0xmedian 23.3x 7.6xmedian 18.0x
P/B now vs peer median 2.2xmedian 2.4x 3.1xmedian 2.4x 0.6xmedian 2.1x
PEG now vs peer median -3.93median 0.87 -3.28median 0.87 —median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBDXDHRGRFS
Revenue $23.25B $25.11B –
Gross profit $10.91B $14.69B –
Operating income $2.48B $5.13B –
Net income $941.00M $4.00B –
Free cash flow $3.20B $5.47B –
R&D $1.37B $1.62B –
EPS (diluted) $3.42 $5.66 –
Cash & equivalents $708.00M $4.35B $969.15M
Total debt $72.81B $26.56B $44.00B
Shares (diluted) 275.16M 707.60M 681.57M
Enterprise value $50.77B $147.52B $1.77B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBDXDHRGRFS
P/E 57.3x 41.0x 11.9x
P/FCF 16.7x 30.0x 7.6x
P/Operating cash flow 13.5x 24.7x –
P/S 2.3x 6.5x 0.6x
P/B 2.2x 3.1x 0.6x
P/Tangible book 2.2x 5.2x 0.9x
EV/EBITDA 14.0x 24.3x –
EV/EBIT 28.0x 36.3x –
EV/Revenue 3.0x 7.4x –
EV/FCF 21.7x 34.0x –
EV/Operating cash flow 17.6x 28.0x –
PEG (3Y EPS CAGR) -3.93 -3.28 –

Growth

14 metrics
MetricBDXDHRGRFS
Revenue growth (1Y) 17.4% 4.6% –
Revenue CAGR (3Y) 6.9% -0.5% –
Gross profit growth (1Y) 23.7% 2.6% –
Gross profit CAGR (3Y) 8.5% -0.9% –
Operating income growth (1Y) 13.0% 16.1% –
Operating income CAGR (3Y) 3.3% -7.1% –
Net income growth (1Y) -40.6% 17.3% –
Net income CAGR (3Y) -17.3% -14.3% –
EPS growth (1Y) -38.0% 19.2% –
EPS CAGR (3Y) -14.6% -12.5% –
Operating cash flow growth (1Y) 43.5% 7.6% –
Operating cash flow CAGR (3Y) 14.5% -7.6% –
Free cash flow growth (1Y) 54.2% 12.4% –
Free cash flow CAGR (3Y) 22.5% -9.0% –

Profitability

14 metrics
MetricBDXDHRGRFS
Gross margin 46.9% 58.5% –
EBITDA margin 21.4% 30.5% –
Operating margin 10.7% 20.4% –
Pretax margin 8.4% 19.0% –
Net margin 4.0% 15.9% –
FCF margin 13.8% 21.8% –
Operating cash flow margin 17.0% 26.4% –
Return on equity 3.9% 7.6% –
Return on assets 1.9% 4.5% –
Return on invested capital 5.3% 5.7% –
Return on capital employed 6.0% 6.4% –
Asset turnover 0.5x 0.3x –
Cash conversion (OCF / net income) 4.2x 1.7x –
Stock comp / revenue 1.2% 1.2% –

Financial Health

11 metrics
MetricBDXDHRGRFS
Debt / assets 33.1% 28.8% 48.9%
Debt / equity 0.7x 0.5x 1.3x
Net debt / EBITDA 3.2x 2.9x –
Debt / FCF 5.2x 4.9x –
Liabilities / assets 51.9% 43.1% 61.4%
Equity / assets 48.1% 56.9% 38.6%
Interest coverage 4.2x 17.6x –
Current ratio 0.9x 1.7x 2.5x
Quick ratio 0.3x 1.0x 0.8x
Cash ratio 0.1x 0.5x 0.4x
Altman Z-score 2.29 3.72 –

Shareholder Returns

7 metrics
MetricBDXDHRGRFS
Dividend yield 2.1% 0.7% 1.4%
Net buyback yield 4.7% 1.8% –
Shareholder yield 6.8% 2.4% 1.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBDXDHRGRFS
Forward P/E 15.1xFY2026 25.6xFY2026 8.4xFY2026
EPS, next fiscal year $12.99FY2026 $9.11FY2026 $0.94FY2026
EPS growth, next FY +14.8%FY2026 +16.8%FY2026 +10.6%FY2026
EPS growth, the year after -2.9% +8.0% +26.6%
Revenue, next fiscal year $18.11BFY2026 $27.01BFY2026 $8.88BFY2026
Revenue growth, next FY -17.1%FY2026 +9.9%FY2026 +0.0%FY2026
Revenue growth, the year after +11.6% -1.9% +10.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBDXDHRGRFS
Held by institutions 96.1% 81.9% 21.0%
Institutions holding 1,442 2,115 166
Change in shares held, QoQ +0.6% +1.1% -0.5%
Institutions buying 688 837 73
Institutions selling 543 1,015 65
Buyers to sellers 1.27 0.82 1.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BDXDHRGRFS
BDX 1.00 0.32 0.27
DHR 0.32 1.00 0.20
GRFS 0.27 0.20 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BDX, DHR and GRFS?

Danaher (DHR) is the largest by market capitalisation: Becton Dickinson (BDX) $53.62B, Danaher (DHR) $163.71B, Grifols (GRFS) $5.43B.

Which stock is cheaper, BDX, DHR and GRFS?

Grifols (GRFS) trades on the lowest price-to-earnings ratio (Becton Dickinson (BDX) 57.0x, Danaher (DHR) 40.9x, Grifols (GRFS) 11.9x). On next year's consensus earnings, Grifols (GRFS) is cheapest (Becton Dickinson (BDX) 15.1x, Danaher (DHR) 25.6x, Grifols (GRFS) 8.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Becton Dickinson (BDX) grew revenue fastest over the trailing twelve months: Becton Dickinson (BDX) +17.4%, Danaher (DHR) +4.6%.

Which company is more profitable?

Danaher (DHR) has the highest net margin (Becton Dickinson (BDX) 4.0%, Danaher (DHR) 15.9%). On return on invested capital, Danaher (DHR) leads (Becton Dickinson (BDX) 5.3%, Danaher (DHR) 5.7%).

Which stock has performed better?

Over the past year Becton Dickinson (BDX) returned the most: Becton Dickinson (BDX) +5.7%, Danaher (DHR) +4.5%, Grifols (GRFS) -16.3%. Over five years, Becton Dickinson (BDX) compounded fastest (Becton Dickinson (BDX) -4.3%/yr, Danaher (DHR) -5.3%/yr, Grifols (GRFS) -9.9%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Becton Dickinson (BDX) 31.9%, Danaher (DHR) 30.7%, Grifols (GRFS) 32.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BDX, DHR and GRFS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.